Standard BioTools Reports Q4 Earnings

The South San Francisco-based company posted revenue of $23.8 million in the quarter.

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

Standard BioTools Inc. (LAB) reported earnings of $19.3 million in its fourth quarter, with net income of 5 cents per share. The company, which makes equipment to control fluids, posted revenue of $23.8 million in the period. For the full year, the company reported a loss of $74.9 million, or 20 cents per share, on revenue of $85.3 million.

Why it matters

Standard BioTools is a major player in the biotech equipment industry, and its quarterly and annual financial results provide insight into the overall health and performance of the sector.

The details

In the fourth quarter, Standard BioTools reported earnings of $19.3 million, or 6 cents per share on an adjusted basis. The company posted revenue of $23.8 million in the period. For the full year, the company reported a loss of $74.9 million, or 20 cents per share, on revenue of $85.3 million.

  • Standard BioTools reported its Q4 and full-year 2025 earnings on Tuesday, February 24, 2026.

The players

Standard BioTools Inc.

A company that makes equipment to control fluids and is based in South San Francisco, California.

Got photos? Submit your photos here. ›

What’s next

Standard BioTools expects full-year 2026 revenue in the range of $80 million to $85 million.

The takeaway

Standard BioTools' financial results provide insight into the overall performance of the biotech equipment industry, which is a critical part of the broader life sciences sector.